Pfizer requests FDA authorization to administer booster dose to children 5-11
Pfizer and BioNTech on Tuesday submitted an application to the Food and Drug Administration (FDA) requesting authorization to administer a booster dose of their COVID-19 vaccine to children aged 5-11.
In its announcement, Pfizer cited data from a Phase 2/3 trial, which it says indicated a “strong immune response” in the younger age group after a booster dose was administered six months after primary immunization with its COVID-19 vaccine.
The companies intend on submitting this same data to other regulatory agencies around the world, including the European Medicines Agency.
A booster dose of Pfizer’s COVID-19 shot has been authorized for adults since September, and more than 100 million people have already received an additional shot, according to the Centers for Disease Control and Prevention (CDC). Around half of the people who are eligible for a booster half not gotten one yet.
Pfizer COVID-19 booster doses for children as young as 12 have been authorized by the FDA since January.
According to the most recent data from the CDC, 28.4 percent of children 5-11 in the U.S. are considered fully vaccinated, and only about 35 percent have received their first dose of a vaccine. Nearly 60 percent of children 12-17 are fully vaccinated.
Pfizer’s application to authorize boosters for children comes about a month after the FDA authorized a second booster dose of the company’s vaccine for people over 50 and immunocompromised individuals as young as 12.
COVID-19 vaccines are still not authorized for children under the age of 5 in the U.S. The Biden administration has recently indicated the FDA will consider both Pfizer’s and Moderna’s requests for coronavirus vaccine administration for this age group later in the summer, possibly in June.
The Hill has removed its comment section, as there are many other forums for readers to participate in the conversation. We invite you to join the discussion on Facebook and Twitter.